In patients with proven ACC, adjuvant mitotane treatment is recommended in patients after radical surgery with a perceived high risk of recurrence (ENSAT stage III, R1 resection or Ki67-index > 10%). The gene discussed is MKI67; the disease is adrenal cortex carcinoma.